(MENAFN- Straits Research)
Inhaled Nitric Oxide Market Size & Growth Analysis
The global inhaled nitric oxide market size was valued at USD 1034.21 million in 2025 and is projected to grow from USD 1121.08 million in 2026 to USD 2137.33 million by 2034, registering a CAGR of 8.4% during the forecast period from 2026 to 2034. North America dominated the inhaled nitric oxide market with a market share of 42.6% in 2025.
Inhaled nitric oxide is a pulmonary vasodilator that regulates vascular muscle tone significantly. It has emerged as a treatment for hypoxemic respiratory failure in newborns with persistently high pulmonary vascular pressure and resulting right-to-left blood shunting (persistent pulmonary hypertension of the newborn).
For example, around 2% of all live births and over 33% of newborn mortality occur annually owing to neonatal hypoxia respiratory failure (HRF). In contrast, 0.4-6.8/1000 live birth years are affected by persistent pulmonary hypertension of the newborn (PPHN). The mortality rate for those with moderate to severe forms of the illness remains around 10%. Neonatal hypoxic respiratory failure is characterized by persistent pulmonary hypertension of the infant and various disorders that contribute to pulmonary arterial hypertension, such as meconium aspiration syndrome, sepsis, birth asphyxia, and respiratory distress syndrome.
Nitric oxide is a selective pulmonary vasodilator administered to the patient by mechanical ventilation following dilution with an oxygen/air mixture nitric oxide delivery device. 100 ppm and 800 ppm quantities of nitric oxide are available depending on the therapy. In addition, clinical trials explore using inhaled nitric oxide for several diseases. The potential therapeutic effect of this in adults is still unknown, and indications approved by the FDA are limited to pediatric practice.
Inhaled Nitric Oxide Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 1.03 Billion
2026 Market Size: USD 1.12 Billion
2034 Projected Market Size: USD 2.14 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 8.4%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.6%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 9.34%
Segment Insights
Application
Leading Segment: Neonatal Respiratory Treatment
Market Share in 2025: 64.8%
Download a Free Sample To learn more about this report,
Inhaled Nitric Oxide Market Trends
Shift Toward Tankless and Point-of-Care Nitric Oxide Systems
Hospitals are increasingly moving from high-pressure nitric oxide cylinders toward compact systems that generate or store gas at the point of care. These platforms reduce cylinder handling, storage needs, delivery delays, and administrative work while supporting treatment during transfers between neonatal intensive care, operating rooms, and other hospital departments. Built-in monitoring of nitric oxide, oxygen, and nitrogen dioxide also improves workflow and treatment control. Competition is therefore shifting from gas supply alone toward portable devices, integrated safety features, technical support, and flexible hospital contracts. This transition is encouraging established suppliers and newer manufacturers to invest in cylinder-free technologies.
In May 2025, Mallinckrodt reported that more than 400 INOmax EVOLVE DS systems had been placed across over 50 U.S. hospitals by the end of March.
Inhaled Nitric Oxide Market Dynamics
Market Drivers
Growing Need for Rapid Respiratory Support in Critical Care
Demand is supported by the need to improve oxygenation in term and near-term newborns with hypoxic respiratory failure linked to pulmonary hypertension. Inhaled nitric oxide selectively relaxes pulmonary blood vessels and can reduce the need for extracorporeal membrane oxygenation when used with ventilatory support. Rising awareness of neonatal respiratory complications, stronger neonatal intensive-care capacity, and broader access to advanced ventilation systems are increasing treatment availability. Respiratory disease also creates research interest beyond neonatal care, including COPD and acute respiratory distress syndrome. The CDC reports that nearly 16 million U.S. adults have COPD, underlining the large respiratory-care burden that encourages further clinical investigation.
Market Restraints
Limited Approved Uses and High Treatment Costs
Market expansion is restricted by the therapy's narrow approved indication, specialized delivery requirements, and substantial hospital costs. In the United States, approved products primarily treat hypoxic respiratory failure associated with pulmonary hypertension in term and near-term newborns. Adult use remains largely off-label or investigational, limiting routine reimbursement and adoption. Treatment also requires calibrated equipment, continuous gas monitoring, trained respiratory professionals, backup delivery arrangements, and careful dose reduction. These requirements make adoption harder for smaller hospitals and facilities in lower-income regions. Price competition from newer delivery systems is also putting pressure on established brands and changing hospital purchasing decisions.
In May 2025, Mallinckrodt reported that first-quarter INOmax sales declined 11% year over year to USD 62.5 million amid U.S. competition.
Market Opportunities
Expansion of Portable Systems and New Clinical Applications
Major opportunities are emerging from cylinder-free delivery, geographic expansion, and research into additional respiratory conditions. Systems that generate nitric oxide from room air can reduce dependence on cylinder transport, storage, replacement, and complex supply arrangements. This could improve access in smaller hospitals, emergency settings, and regions with weak medical-gas infrastructure. Manufacturers can also pursue growth through distributor partnerships, hospital purchasing agreements, and devices suitable for transport between care departments. Longer-term opportunities exist in viral pneumonia, COPD, pulmonary hypertension, and acute respiratory distress syndrome, although these applications require strong clinical evidence and regulatory clearance before broad commercialization.
In December 2025, Beyond Air announced LungFit PH distribution agreements covering Germany and Brazil, extending its cylinder-free platform into additional international markets.
Market Challenges
Maintaining Safety, Consistent Dosing, and Clinical Evidence
Inhaled nitric oxide must be delivered accurately because treatment errors can quickly affect critically ill patients. Nitrogen dioxide may form when nitric oxide mixes with oxygen, potentially causing airway inflammation and lung injury. Higher exposure can also raise methemoglobin levels and reduce the blood's oxygen-carrying capacity. Abrupt withdrawal may worsen oxygenation and trigger rebound pulmonary hypertension, making controlled weaning essential. Suppliers must therefore provide dependable monitoring, backup delivery, equipment maintenance, clinician training, and uninterrupted service. Another challenge is demonstrating meaningful long-term outcomes beyond temporary oxygenation improvement, especially for adult and off-label applications where evidence remains mixed and regulatory approval is limited.
In April 2026, Health Canada's INOmax monograph required methemoglobin monitoring and dose reduction when levels exceed 2.5%, highlighting the therapy's strict safety demands.
Inhaled Nitric Oxide Market Segmentation Analysis
By Application
The neonatal respiratory treatment segment dominated the inhaled nitric oxide market with a 64.8% market share, valued at USD 0.67 billion, and is projected to register a CAGR of 7.63%. Its leading position is supported by the established use of inhaled nitric oxide for term and near-term newborns experiencing hypoxic respiratory failure associated with pulmonary hypertension. The treatment selectively widens pulmonary blood vessels, improves oxygenation, and can reduce the need for extracorporeal membrane oxygenation. Expanding neonatal intensive care capacity, improved diagnosis of respiratory complications, and growing availability of advanced delivery systems continue to support demand across hospitals and specialized pediatric care centers.
Chronic obstructive pulmonary disease represents an emerging application as healthcare professionals investigate inhaled nitric oxide for patients experiencing pulmonary hypertension and impaired oxygen exchange. Its use in this population remains limited by mixed clinical outcomes, narrow regulatory indications, and the need for carefully controlled administration. Acute respiratory distress syndrome is attracting stronger research interest because inhaled nitric oxide can temporarily improve oxygenation in critically ill patients by directing blood flow toward better-ventilated areas of the lungs. However, uncertain effects on mortality, treatment expenses, and intensive monitoring requirements continue to restrict routine adoption for both adult respiratory applications.
Request Customization to receive a tailored report.
Speak to an Analyst to discuss market opportunities.
Inhaled Nitric Oxide Market Regional Outlook
North America Inhaled Nitric Oxide Market Analysis
North America dominated the inhaled nitric oxide market with a 42.6% market share and a value of USD 0.44 billion. The regional market is projected to expand at a CAGR of 7.45%. Its leading position is supported by established neonatal intensive care infrastructure, access to advanced respiratory treatment, and the presence of major nitric oxide suppliers and delivery-system manufacturers. Hospitals across the region increasingly focus on portable, tankless, and accurately monitored delivery platforms. Continued clinical use for neonatal hypoxic respiratory failure, strong specialist expertise, and investments in modern critical-care equipment are expected to sustain regional demand.
United States Inhaled Nitric Oxide Market Insights
The United States is a major contributor to the North American inhaled nitric oxide market because of its advanced neonatal intensive care network and broad availability of respiratory specialists. Hospitals use inhaled nitric oxide primarily to improve oxygenation in eligible newborns with hypoxic respiratory failure and pulmonary hypertension. The presence of established manufacturers encourages competition in portable and tankless delivery systems, integrated gas monitoring, and hospital support services. Clear regulatory requirements, established reimbursement channels, clinical training programs, and strong critical-care capabilities promote treatment adoption. Research into additional respiratory applications also creates development opportunities, although broader use depends on convincing clinical evidence and regulatory authorization.
Canada Inhaled Nitric Oxide Market Insights
Canada supports the inhaled nitric oxide market through its publicly funded hospital system, specialized pediatric centers, and emphasis on evidence-based neonatal care. Demand is concentrated in facilities that manage severe respiratory complications and can provide continuous monitoring, mechanical ventilation, and trained clinical support. Healthcare providers prioritize treatment safety, reliable medical-gas supply, and gradual patient weaning to reduce complications. Procurement decisions are influenced by equipment quality, operating efficiency, technical assistance, and the ability to maintain uninterrupted therapy. Opportunities for portable and cylinder-free systems may increase as hospitals seek to simplify gas handling and patient transfers while maintaining consistent treatment standards across critical-care departments.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Inhaled Nitric Oxide Market Analysis
Asia Pacific is the fastest-growing regional inhaled nitric oxide market, with a 21.8% market share and a value of USD 0.23 billion. The region is forecast to record the highest CAGR of 9.34%. Growth is supported by expanding neonatal intensive care services, rising investment in hospital infrastructure, and increasing recognition of pulmonary hypertension and hypoxic respiratory failure in newborns. Demand is also benefiting from improved access to mechanical ventilation and specialized respiratory care. International manufacturers and regional distributors have opportunities to introduce portable delivery systems, clinical training, and maintenance services as healthcare institutions modernize critical-care capabilities across developed and emerging economies.
Japan Inhaled Nitric Oxide Market Insights
Japan represents an important market for inhaled nitric oxide because of its advanced hospital infrastructure, experienced neonatal specialists, and strong adoption of sophisticated medical equipment. Healthcare facilities emphasize precise dosing, continuous monitoring, dependable backup systems, and controlled treatment withdrawal. Demand is supported by well-equipped neonatal intensive care units and established clinical pathways for managing pulmonary hypertension and severe oxygenation problems in newborns. Medical-device suppliers can strengthen their positions by providing compact equipment, responsive maintenance, and comprehensive clinician training. The country's focus on patient safety and technology-driven care also encourages hospitals to consider delivery platforms that simplify workflow and support movement between intensive-care and surgical environments.
China Inhaled Nitric Oxide Market Insights
China offers substantial development potential for the inhaled nitric oxide market as hospitals expand neonatal and respiratory critical-care capabilities. Greater availability of specialist facilities is improving access to advanced treatment for newborns experiencing serious oxygenation difficulties and pulmonary hypertension. Demand varies between major urban hospitals and facilities in less-developed areas because equipment access, clinical experience, and medical-gas infrastructure remain uneven. Manufacturers can address this gap through portable systems, local distribution partnerships, clinician education, and dependable after-sales support. Domestic production and wider hospital procurement may also improve availability, although adoption will continue to depend on regulatory compliance, treatment affordability, technical reliability, and confidence among healthcare professionals.
Europe Inhaled Nitric Oxide Market Analysis
Europe accounted for a 27.4% share of the inhaled nitric oxide market, representing a value of USD 0.28 billion. The regional market is anticipated to grow at a CAGR of 7.18%. Demand is supported by established neonatal care networks, advanced critical-care facilities, and consistent use of respiratory therapies in major healthcare systems. European hospitals place considerable emphasis on treatment protocols, patient monitoring, equipment safety, and cost-effective procurement. The adoption of portable and tankless delivery solutions may help reduce cylinder storage and handling requirements. However, strict regulatory standards and budget controls influence product selection and the pace of technology adoption across individual countries.
Germany Inhaled Nitric Oxide Market Insights
Germany supports the inhaled nitric oxide market through its extensive hospital network, specialist neonatal centers, and strong medical-technology sector. Clinical demand is associated mainly with severe respiratory failure and pulmonary hypertension in eligible newborns requiring ventilatory support. Hospitals evaluate delivery systems based on dosing accuracy, alarm functions, gas monitoring, backup capability, and compatibility with existing ventilation equipment. Manufacturers can gain an advantage by offering reliable maintenance, professional training, and efficient supply arrangements. Interest in cylinder-free generation may grow as healthcare providers seek to reduce storage needs and simplify clinical workflows, although purchasing decisions remain influenced by evidence of therapeutic value, regulatory compliance, and hospital budget priorities.
United Kingdom Inhaled Nitric Oxide Market Insights
The United Kingdom inhaled nitric oxide market is supported by specialist neonatal units, established critical-care guidelines, and centralized healthcare procurement. Treatment is generally concentrated in hospitals capable of providing mechanical ventilation, continuous monitoring, and experienced respiratory support. Clinical teams carefully assess patient eligibility because inhaled nitric oxide requires controlled administration and may not produce the same outcome across all respiratory conditions. Suppliers must demonstrate equipment reliability, service availability, and clear operational benefits to secure hospital adoption. Portable and tankless systems may create opportunities by reducing cylinder management and supporting safer patient transfers, but cost-effectiveness and strong clinical evidence remain important considerations for healthcare decision-makers.
Latin America Inhaled Nitric Oxide Market Analysis
Latin America held a 4.7% share of the inhaled nitric oxide market and generated a value of USD 0.05 billion. The region is expected to advance at a CAGR of 7.62%. Market growth is associated with gradual improvements in neonatal intensive care, expansion of private hospital networks, and increasing awareness of advanced respiratory therapies. Limited access to specialized equipment and trained personnel continues to affect adoption in some areas. Suppliers can support growth through local distribution, equipment leasing, technical training, and dependable maintenance. Portable systems may be particularly valuable where cylinder transportation and storage create operational difficulties for healthcare institutions.
Brazil Inhaled Nitric Oxide Market Insights
Brazil is a key country within the Latin American inhaled nitric oxide market because of its large hospital network and continued development of neonatal intensive-care services. Major urban medical centers are better positioned to provide inhaled nitric oxide therapy because they have advanced ventilation systems, respiratory specialists, and continuous patient-monitoring capabilities. Access remains less consistent outside leading healthcare centers, creating a need for affordable equipment, local technical assistance, and clinician education. Partnerships between manufacturers, distributors, and hospitals can improve product availability and maintenance coverage. Portable or cylinder-free delivery systems may also help overcome logistical barriers, provided they meet national regulatory requirements and hospital procurement standards.
Middle East and Africa Inhaled Nitric Oxide Market Analysis
The Middle East and Africa represented 3.5% of the inhaled nitric oxide market, with a value of USD 0.04 billion. The regional market is projected to grow at a CAGR of 7.29%. Development is supported by investment in advanced hospitals, neonatal intensive-care units, and specialist respiratory services, particularly in wealthier healthcare markets. However, access remains uneven because many facilities face limited equipment availability, medical-gas supply challenges, and shortages of trained professionals. International suppliers can expand through distributor partnerships, training programs, and portable delivery platforms. Affordability, maintenance access, and dependable technical support will remain important factors shaping adoption throughout the region.
UAE Inhaled Nitric Oxide Market Insights
The United Arab Emirates offers growth opportunities for the inhaled nitric oxide market through continued investment in advanced hospitals, specialist pediatric services, and modern critical-care technology. Leading healthcare facilities can support complex neonatal respiratory treatment with trained clinical teams, mechanical ventilation, and continuous gas monitoring. The country also functions as a regional healthcare and distribution center, creating opportunities for international suppliers to establish partnerships and provide technical support. Hospitals are likely to favor delivery systems that improve portability, reduce cylinder handling, and integrate smoothly with existing equipment. Product quality, regulatory approval, clinician training, maintenance availability, and reliable supply remain central to procurement and adoption decisions.
Inhaled Nitric Oxide Market Competitive Landscape
Competition centers on therapeutic gas reliability, portable delivery systems, hospital contracts, clinical support, and cylinder-free technology. Mallinckrodt's INOmax remains an established brand, while VERO Biotech's GENOSYL and Beyond Air's LungFit PH compete through tankless or point-of-care delivery models. Air Liquide, Linde, BOC Healthcare, and other medical-gas companies benefit from established production and distribution networks. Device differentiation is increasingly important because hospitals want easier transport, reduced storage, automated monitoring, dependable backups, and lower operational burden. Pricing pressure is visible as alternative platforms gain placements, forcing suppliers to strengthen service agreements, purchasing-group access, international distribution, and next-generation equipment.
List of Key and Emerging Players in Inhaled Nitric Oxide Market
Air Liquide S.A.
Bellerophon Therapeutics Inc.
BOC Healthcare
Beyond Air Inc.
Halma Plc
Linde Plc (Praxair Inc.)
Mallinckrodt Plc
Novoteris LLC
Vero Biotech Llc
Nu-Med Plus
Key Industry Developments
March 2026: Beyond Air expanded commercialization of its LungFit® PH inhaled nitric oxide delivery system by securing a national group purchasing agreement (GPO) in the United States and expanding its global distribution network to more than 45 countries. The expansion supports broader adoption of cylinder-free nitric oxide generation technology in neonatal intensive care and respiratory care settings.
May 2025: VERO Biotech expanded adoption of its GENOSYL® Delivery System, an FDA-approved tankless inhaled nitric oxide delivery platform designed for acute care applications. The company continued strengthening its commercial presence in respiratory care by supporting hospitals with integrated nitric oxide delivery solutions.
October 2025: Mallinckrodt Pharmaceuticals continued supporting its INOmax® (nitric oxide) gas therapy platform, which remains one of the established inhaled nitric oxide therapies for neonatal respiratory care. The company maintained focus on supply reliability, clinical support, and healthcare provider access for nitric oxide treatment.
Report Scope
Comments
No comment